The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Robert G. Gish

Division of Hepatology and Complex GI

Physicians Foundation California Pacific Medical Center

San Francisco

CA 94115-1932

USA

[email]@sutterhealth.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hepatology and Complex GI, Physicians Foundation California Pacific Medical Center, San Francisco, CA 94115-1932, USA. 2005 - 2010
  • Liver Transplant Program, California Pacific Medical Center, San Francisco, California 94115, USA. 1999 - 2008
  • California Pacific Medical Center, Liver Transplant Program, Division of Hepatology and Complex GI, 2340 Clay Street, USA. 2006

References

  1. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. Gish, R.G., Chang, T.T., Lai, C.L., de Man, R., Gadano, A., Poordad, F., Yang, J., Brett-Smith, H., Tamez, R. J. Viral Hepat. (2010) [Pubmed]
  2. Hepatitis B treatment: Current best practices, avoiding resistance. Gish, R.G. Cleve. Clin. J. Med (2009) [Pubmed]
  3. Monotherapy vs multiple-drug therapy: the experts debate. Gish, R.G., Gholam, P.M. Cleve. Clin. J. Med (2009) [Pubmed]
  4. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Gish, R.G., Gordon, S.C., Nelson, D., Rustgi, V., Rios, I. Hepatology. International (2009) [Pubmed]
  5. Diagnosis of chronic hepatitis B and the implications of viral variants and mutations. Gish, R.G. Am. J. Med. (2008) [Pubmed]
  6. Hepatocellular carcinoma (HCC): current and evolving therapies. Gish, R.G., Baron, A. IDrugs (2008) [Pubmed]
  7. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. Gish, R.G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A., Feun, L., Jeziorski, K., Leighton, J., Gallo, J., Kennealey, G.T. J. Clin. Oncol. (2007) [Pubmed]
  8. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. Gish, R.G., Arora, S., Rajender Reddy, K., Nelson, D.R., O'Brien, C., Xu, Y., Murphy, B. J. Hepatol. (2007) [Pubmed]
  9. Improving outcomes for patients with chronic hepatitis B. Gish, R.G. Curr. Gastroenterol. Rep (2007) [Pubmed]
  10. Chronic hepatitis B: current epidemiology in the Americas and implications for management. Gish, R.G., Gadano, A.C. J. Viral Hepat. (2006) [Pubmed]
  11. Treating HCV with ribavirin analogues and ribavirin-like molecules. Gish, R.G. J. Antimicrob. Chemother. (2006) [Pubmed]
  12. Hepatocellular carcinoma: overcoming challenges in disease management. Gish, R.G. Clin. Gastroenterol. Hepatol. (2006) [Pubmed]
  13. Chronic hepatitis B: current testing strategies. Gish, R.G., Locarnini, S.A. Clin. Gastroenterol. Hepatol. (2006) [Pubmed]
  14. Hepatitis B in liver transplant recipients. Gish, R.G., McCashland, T. Liver Transpl. (2006) [Pubmed]
  15. Management of hepatitis C virus in special populations: patient and treatment considerations. Gish, R.G., Afdhal, N.H., Dieterich, D.T., Reddy, K.R. Clin. Gastroenterol. Hepatol. (2005) [Pubmed]
  16. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Gish, R.G. Semin. Liver Dis. (2005) [Pubmed]
  17. Current treatment and future directions in the management of chronic hepatitis B viral infection. Gish, R.G. Clin. Liver. Dis (2005) [Pubmed]
  18. Treating hepatitis C: the state of the art. Gish, R.G. Gastroenterol. Clin. North Am. (2004) [Pubmed]
  19. Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects. Gish, R.G. Gastroenterol. Clin. North Am. (2004) [Pubmed]
  20. Autoimmune liver disease. Current standards, future directions. Gish, R.G., Mason, A. Clin. Liver. Dis (2001) [Pubmed]
  21. Future directions in the treatment of patients with chronic hepatitis C virus infection. Gish, R.G. Can. J. Gastroenterol. (1999) [Pubmed]
  22. Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. Gish, R.G., Qian, K., Brooks, L., Leung, J., Xu, Y., Pike, I., Lau, J.Y. J. Gastroenterol. Hepatol. (1999) [Pubmed]
 
WikiGenes - Universities